Percutaneous vertebroplasty versus non-operative treatment for osteoporotic vertebral compression fractures: a meta-analysis of randomized controlled trials

Lou, Shenghan; Shi, Xu; Zhang, X; Lyu, Houchen; Li, Z; Wang, Y

doi:10.1007/s00198-019-05101-8

Cited by 60 publications

(43 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteoporosis is a relatively prevalent disease that mainly leads to loss of bone mass and microstructural deterioration of bone tissues and eventually increases the susceptibility of patients to bone fractures [16,17]. It has been found that abnormal expression of many genes can cause osteoporosis, among which RUNX2 is the key transcription factor regulating osteoblast differentiation and bone formation during bone development [18,19].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-505 is involved in the regulation of osteogenic differentiation of MC3T3-E1 cells partially by targeting RUNX2

Chen

Cai

et al. 2020

J Orthop Surg Res

View full text Add to dashboard Cite

Objective: Evidence suggests that microRNAs (miRNAs) regulate the expression of genes involved in bone metabolism. This study aimed to investigate the role of miR-505 in the osteogenic differentiation of MC3T3-E1 cells. Methods: We performed miRNA sequencing to identify differentially expressed miRNAs between MC3T3-E1 cells treated with osteogenic induction medium (OIM) and control cells. Bioinformatics analysis was performed by using the TargetScan and miRDB databases. The expression of miR-505 in MC3T3-E1 cells was detected during osteogenic differentiation. After transfection with miR-505 mimic or miR-505 inhibitor, MC3T3-E1 cells were induced to differentiate into osteoblasts, and the expression of osteogenic differentiation markers (Runt-related transcription factor 2 (RUNX2), alkaline phosphatase (ALP), osteopontin (OPN), osteocalcin (OCN), and osterix (OSX)) was detected. Results: miR-505 was the most downregulated miRNA among the differentially expressed miRNAs. The RUNX2 gene was identified as a potential target of miR-505 using the target prediction program. miR-505 expression was downregulated during osteogenic differentiation of MC3T3-E1 cells. The expression of osteogenic marker genes was inhibited in MC3T3-E1 cells after transfection with miR-505. However, the expression of osteogenic marker genes was upregulated after transfection with miR-505 inhibitor.Conclusion: This study is the first to report miR-505 could bind to the RUNX2 gene and thus regulate partly the dysfunction of osteoblasts differentiation, which is expected to be targets for the treatment of osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA-505 is involved in the regulation of osteogenic differentiation of MC3T3-E1 cells partially by targeting RUNX2

Chen

Cai

et al. 2020

J Orthop Surg Res

View full text Add to dashboard Cite

show abstract

“…The risk of refracture of the adjacent vertebral body after vertebral augmentation remains controversial. The incidence of new VCFs after vertebroplasty is around 8-16% [16,17], which is close to that of the natural history of patients with first time VCF. As a result, some authors argue that these re-fractures are the result of the natural progression of osteoporosis in high-risk patients [18] instead of the mechanical effect of the procedure itself.…”

Section: Surgical Management Of Osteoporotic Vcfmentioning

confidence: 73%

Update on Symptomatic Treatment of Acute Vertebral Compression Fracture

Wong

Mok

2019

Journal of Clinical Rheumatology and Immunology

View full text Add to dashboard Cite

The vertebral column is the most common site of osteoporotic fracture in older individuals and in those using long-term glucocorticoids. Vertebral compression fracture leads to significant morbidities such as acute and chronic pain, spinal deformities and neurological complications, resulting in reduced mobility and quality of life. As a previous vertebral compression fracture is a strong risk factor for further fragility fractures and mortality, it should be treated appropriately. This article reviews the management of osteoporotic vertebral compression fracture and provides evidence-based treatment options.

show abstract

“…The goal of the treatment is to stop the progression of vertebral necrosis and rebuild spinal stability. Conservative treatment can make patients enter a vicious circle of ischemia and necrosis, while open surgery is not the best choice due to the large injury and slow recovery of elderly patients [15]. PVP technology has become the preferred method with the advantages of minimum injury and quick recovery.…”

Section: Resultsmentioning

confidence: 99%

Comparison of the clinical manifestations and cement distribution after percutaneous vertebroplasty between thoracolumbar Kümmell’s disease and OVCFs

Wang¹,

Chen

2020

Preprint

View full text Add to dashboard Cite

Background：Kümmell's disease is a chronic, non-healing osteoporotic vertebral compression fractures (OVCFs), which is associated with ischemic necrosis and vertebral pseudarthrosis. The purpose of this study was to compare the therapeutic effect and distribution characteristics of bone cement in the percutaneous vertebroplasty (PVP) treatment between thoracolumbar Kümmell's diseases and OVCFs.Methods: A total of 70 patients with Kümmell ’s disease (K group) or OVCFs (O group) who underwent PVP surgery from February 2016 to February 2018 were included in this study. The follow-up time was 24-48 months. The course of disease was significantly longer in the K group than in the O group (P=0.000). Most cases in the K group had no history of trauma, while most cases in the O group had a history of falls (P=0.001). The vertebral compression rate and degree of osteoporosis were more serious in the K group than in the O group (P<0.05, respectively). Distribution pattern, volume and leakage rate of bone cement, operation time, VAS score, ODI, correction rates of vertebral compression and kyphosis, re-fracture rate of adjacent vertebrae between the two groups were compared to assess clinical effect.Results: The amount of bone cement injected was significantly higher in the K group than in the O group (P=0.025). The cement distribution pattern of local solid lump was dominant in the K group (65.71%), while intercalation with trabeculae was dominant in the O group (74.29%) (P<0.001). VAS and ODI were significantly lower both in the two groups at the 1st day, 1st year and 2nd years after surgery than before surgery (all P<0.05), but significantly lower in the K group than in the O group at each time point after surgery (all P<0.05). The correction rates of kyphosis and vertebral compression in both groups were significantly improved (P<0.05, respectively) and gradually lost with time (P<0.05, respectively). The correction rates of kyphosis and vertebral compression were significantly higher in the K group than in the O group at each time point after surgery (all P<0.05).Conclusion: Kümmell's disease has a higher degree of disease progression and osteoporosis than OVCFs. PVP can better restore partial vertebral height and correct kyphosis in the treatment of Kümmell's disease, while can better alleviate pain and improve ODI in the treatment of OVCFs.

show abstract

Percutaneous vertebroplasty versus non-operative treatment for osteoporotic vertebral compression fractures: a meta-analysis of randomized controlled trials

Cited by 60 publications

References 37 publications

MicroRNA-505 is involved in the regulation of osteogenic differentiation of MC3T3-E1 cells partially by targeting RUNX2

MicroRNA-505 is involved in the regulation of osteogenic differentiation of MC3T3-E1 cells partially by targeting RUNX2

Update on Symptomatic Treatment of Acute Vertebral Compression Fracture

Comparison of the clinical manifestations and cement distribution after percutaneous vertebroplasty between thoracolumbar Kümmell’s disease and OVCFs

Contact Info

Product

Resources

About